{"This": [0], "selection": [1], "from": [2], "the": [3, 21, 59, 101, 105, 119], "NCCN": [4, 106], "Clinical": [5], "Practice": [6], "Guidelines": [7, 107], "in": [8, 100, 118], "Oncology": [9], "(NCCN": [10], "Guidelines)": [11], "for": [12, 20, 42, 48, 66, 78, 108], "Colon": [13, 109], "Cancer": [14, 110], "focuses": [15], "on": [16], "systemic": [17, 70], "therapy": [18, 71, 76], "options": [19, 77], "treatment": [22], "of": [23, 45, 61, 92, 104], "metastatic": [24, 96], "colorectal": [25], "cancer": [26], "(mCRC),": [27], "because": [28], "important": [29], "updates": [30, 39], "have": [31], "recently": [32], "been": [33], "made": [34], "to": [35, 58], "this": [36], "section.": [37], "These": [38], "include": [40, 74, 122], "recommendations": [41, 56, 65, 72], "first-line": [43], "use": [44, 60], "checkpoint": [46], "inhibitors": [47], "mCRC,": [49], "that": [50, 82], "is": [51, 83], "deficient": [52], "mismatch": [53], "repair/microsatellite": [54], "instability-high,": [55], "related": [57], "biosimilars,": [62], "and": [63, 90, 129], "expanded": [64], "biomarker": [67], "testing.": [68], "The": [69], "now": [73], "targeted": [75], "patients": [79], "with": [80], "mCRC": [81], "HER2-amplified,": [84], "or": [85, 94], "BRAF": [86], "V600E": [87], "mutation\u2013positive.": [88], "Treatment": [89], "management": [91], "nonmetastatic": [93], "resectable/ablatable": [95], "disease": [97], "are": [98], "discussed": [99], "complete": [102, 120], "version": [103, 121], "available": [111], "at": [112], "NCCN.org": [113], ".": [114], "Additional": [115], "topics": [116], "covered": [117], "risk": [123], "assessment,": [124], "staging,": [125], "pathology,": [126], "posttreatment": [127], "surveillance,": [128], "survivorship.": [130]}